RIMSO-50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rimso-50, and what generic alternatives are available?
Rimso-50 is a drug marketed by Mylan Institutional and is included in one NDA.
The generic ingredient in RIMSO-50 is dimethyl sulfoxide. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the dimethyl sulfoxide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rimso-50
A generic version of RIMSO-50 was approved as dimethyl sulfoxide by RENOVA PHARMS on July 7th, 2026.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RIMSO-50?
- What are the global sales for RIMSO-50?
- What is Average Wholesale Price for RIMSO-50?
Summary for RIMSO-50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 222 |
| Patent Applications: | 2,416 |
| Drug Prices: | Drug price information for RIMSO-50 |
| What excipients (inactive ingredients) are in RIMSO-50? | RIMSO-50 excipients list |
| DailyMed Link: | RIMSO-50 at DailyMed |
US Patents and Regulatory Information for RIMSO-50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Institutional | RIMSO-50 | dimethyl sulfoxide | SOLUTION;INTRAVESICAL | 017788-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RIMSO-50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Institutional | RIMSO-50 | dimethyl sulfoxide | SOLUTION;INTRAVESICAL | 017788-001 | Approved Prior to Jan 1, 1982 | 3,549,770 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RIMSO-50
See the table below for patents covering RIMSO-50 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 644613 | ⤷ Start Trial | |
| Belgium | 644614 | ⤷ Start Trial | |
| Belgium | 644615 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RIMSO-50
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0300652 | SPC/GB03/005 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: D-MEDETOMIDINE (4-((1S)-1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE) AND ITS NON-TOXIC PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE HYDROCHLORIDE; REGISTERED: UK EU/2/02/033/001 20020830 |
| 0284288 | SPC/GB98/002 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 |
| 1131065 | C300675 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DIMETHYLFUMARAAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch